Skip to main content
European Commission logo print header

Biochemical and functional characterization of antigen presenting cell derived-exosomes: the design of a cell free cancer vaccine

Objectif

This proposal is a combined R&D and demonstration project aimed at developing a novel therapeutic substance effective as cancer vaccine. The consortium has a unique expertise in a novel cell free vaccine i.e. the exosomes, 60-90 nm antigen presenting membrane vesicles of endosomal origin, secreted by antigen presenting cells. Characterization of exosome bioactivity will allow neosynthesis of biovectors endowed with targeting and tumor antigen transfer capacities to antigen presenting cells for active immunization. R&D objectives will be to:
1) define the biogenesis and biochemica composition of exasomes.
2) investigate their in vitra and in viva functians.
3) optimise the immunizing strategy using exosomes in preclinical tumor studies
4) design "universal" exosome based-cancer vaccine using good manufactoring procedures.

Demonstration phase involving the SME will show exosome safety and efficacy in immunizing metastatic cancer bearing patients.

Appel à propositions

Data not available

Régime de financement

DEM - Demonstration contracts

Coordinateur

INSTITUT GUSTAVE ROUSSY
Contribution de l’UE
Aucune donnée
Adresse


France

Voir sur la carte

Liens
Coût total
Aucune donnée

Participants (5)